Macrogenics (MGNX) Liabilities and Shareholders Equity (2012 - 2026)

Macrogenics (MGNX) has reported Liabilities and Shareholders Equity for 15 consecutive years, with $217.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 2.98% year-over-year to $217.9 million; the TTM figure through Mar 2026 stood at $990.9 million (up 4.1% YoY), while the FY2025 annual figure was $256.8 million, down 1.84% from the prior year.
• Liabilities and Shareholders Equity slipped to $217.9 million in Q1 2026 per MGNX's latest filing, from $256.8 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $343.5 million in Q1 2023 and bottomed at $195.3 million in Q3 2022.
• Historically, Liabilities and Shareholders Equity has averaged $261.4 million across 5 years, with a median of $261.7 million in 2024.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity sank 50.19% — and 2023, when it surged 74.03%.
• Macrogenics' Liabilities and Shareholders Equity stood at $280.5 million in 2022, then climbed by 6.4% to $298.4 million in 2023, then retreated by 12.32% to $261.7 million in 2024, then slipped by 1.84% to $256.8 million in 2025, then decreased by 15.17% to $217.9 million in 2026.
• Business Quant data shows MGNX's Liabilities and Shareholders Equity at $217.9 million in Q1 2026, $256.8 million in Q4 2025, and $270.8 million in Q3 2025.